JSC Pharmstandard-Leksredstva 2011 AR2
The report highlights Pharmstandard's financial and operational performance for the fiscal year 2011, marking the fifth anniversary of the company's IPO. Key achievements include reaching a record revenue of RUR 42.6 billion, representing a 44% growth compared to the previous year, and the successful acquisition of a 55% stake in PJSC Biolek in Ukraine. The company completed the construction of the R&D Centre Generium and localized the production of the biotechnological product Mabthera in Russia. Additionally, Pharmstandard expanded its workforce to 5,966 employees and continued its transition toward European GMP standards across its manufacturing facilities.
Company: JSC Pharmstandard-Leksredstva
Sector: Manufacturing
Country: Russia
Year: 2011
Type: AR2
Pages: 144
Back to company
JSC Pharmstandard-Leksredstva
Annual Report
The report highlights Pharmstandard's financial and operational performance for the fiscal year 2011, marking the fifth anniversary of the company's IPO. Key achievements include reaching a record revenue of RUR 42.6 billion, representing a 44% growth compared to the previous year, and the successful acquisition of a 55% stake in PJSC Biolek in Ukraine. The company completed the construction of the R&D Centre Generium and localized the production of the biotechnological product Mabthera in Russia. Additionally, Pharmstandard expanded its workforce to 5,966 employees and continued its transition toward European GMP standards across its manufacturing facilities.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2011
Reporting Period
Jan 1, 2011 - Dec 31, 2011
Fiscal Year
2011
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees